论文部分内容阅读
目的观察吉西他滨联合亚砷酸治疗不能切除肝癌的临床疗效。方法 68例患者随机分为观察组和对照组各34例,对照组采用吉西他滨联合奥沙利铂化疗,观察组采用吉西他滨联合亚砷酸化疗,比较两组的疗效和毒副反应。结果全部患者均可评价疗效,两组有效率和疾病控制率均无明显差别(26.5%vs.17.6%,70.6%vs.55.9%,P>0.05)。观察组骨髓抑制和胃肠道反应的发生率显著低于对照组(P<0.05);观察组中位肿瘤进展时间为7.6个月,中位生存期为12.4个月,半年、1年、2年生存率分别为73.5%、55.9%和26.5%,对照组的中位肿瘤进展时间为5.8个月,中位生存期为9.7个月,半年、1年、2年生存率分别为47.1%、26.5%和5.9%,两组比较差异均有统计学意义(P<0.05)。结论吉西他滨联合亚砷酸治疗不能切除肝癌具有良好的临床疗效,毒副反应较轻,值得临床推广。
Objective To observe the clinical efficacy of gemcitabine plus arsenious acid in the treatment of unresectable liver cancer. Methods Sixty-eight patients were randomly divided into observation group and control group, 34 cases in each group. The control group was treated with gemcitabine combined with oxaliplatin. The observation group was treated with gemcitabine and arsenic trioxide. The curative effect and toxicity were compared between the two groups. Results All patients could evaluate the curative effect. There was no significant difference between the two groups in the effective rate and disease control rate (26.5% vs.17.6%, 70.6% vs.55.9%, P> 0.05). The incidence of myelosuppression and gastrointestinal reaction in the observation group was significantly lower than that in the control group (P <0.05). The median tumor progression time in the observation group was 7.6 months, and the median survival time was 12.4 months, 6 months, 1 year, 2 The annual survival rates were 73.5%, 55.9% and 26.5% respectively. The median tumor progression time in the control group was 5.8 months and the median survival time was 9.7 months. The half-year, 1-year and 2-year survival rates were 47.1% 26.5% and 5.9%, respectively, with significant difference between the two groups (P <0.05). Conclusion Gemcitabine combined with arsenic trioxide treatment can not remove the liver cancer has good clinical efficacy, mild side effects, it is worth clinical promotion.